Association of Statin Discontinuation in Pregnancy With Maternal Cardiovascular Health and Birth Outcomes: A Nationwide Cohort Study
Main finding · Maternal MACCEResult — go to the resultHazard ratio 1.00 95% CI 0.72–1.37Authors' conclusion
In this nationwide cohort, discontinuation of statins at pregnancy was not associated with increased maternal cardiovascular risk, including among high-risk women.
Study context
- Population
- Women using statins for 12 to 24 weeks before their last menstrual period (LMP), South Korea National Health Insurance Database, 2010–2022
- Participants
- 13,374 women
- Exposure
- Statin discontinuation before LMP vs continued statin
- Discontinued statinn = 5,881
- Continued statinn = 7,493reference
- Outcome
- Maternal major adverse cardiovascular and cerebrovascular events (MACCE):
- MI
- Stroke
- Coronary revascularization
- CV death
Methodological detailspropensity-score overlap weighting
- Propensity-score overlap weighting
Main finding
Maternal MACCE
Hazard ratio
1.00
95% CI 0.72–1.37
Discontinued statinvs Continued statin
HR 1.00 (95% CI 0.72–1.37)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| MACCE, established familial hypercholesterolemia (subgroup)n=2435; no significant difference | 0.92 (0.46–1.85) | |
| MACCE, atherosclerotic CVD (subgroup)n=1879; no significant difference | 0.83 (0.46–1.49) | |
| 0.512Hazard ratio (log scale) |
Nonlive birth
- Statin discontinuation associated with lower risk of nonlive birth: RR
- 0.89 (95% CI 0.82-0.95)
Low birth weight
- Statin discontinuation associated with lower risk of low birth weight: RR
- 0.88 (95% CI 0.78-0.99)
Original publication
Association of Statin Discontinuation in Pregnancy With Maternal Cardiovascular Health and Birth Outcomes: A Nationwide Cohort Study. Circulation. Published 23 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →